Prior to joining Safeguard, Dr. Pellini was Chief Operating Officer at Lakewood Pathology Associates, Inc., a Lakewood, NJ-based national anatomical pathology company. From 1999 to 2004 Dr. Pellini served as President and CEO of Genomics Collaborative Inc., a Boston, MA-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004. He is also a former Entrepreneur in Residence at BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, where he was responsible for reviewing and evaluating seed stage investment proposals.
Dr. Pellini earned a bachelor's degree from Boston College, an MBA from Drexel University and his MD from Jefferson Medical College of Thomas Jefferson University. Dr. Pellini will remain a member of Clarient's Board of Directors. The Company expects his tenure as COO to last through the second quarter of 2008.
In other senior management moves, Clarient also announced that Karen K. Garza, Senior Vice President, Strategic Planning and Business Development, and Jose de la Torre-Bueno, PhD., Senior Vice President and Chief Technology Officer, will be leaving the company following an interim period of transitional consulting. Andrews said that both Garza and Torre-Bueno have played critical roles in the formation, transformation, growth and success of Clarient. "On behalf of the entire Clarient team, I want to thank Karen and Jose for their tireless efforts and wish them both the best in future endeavors," Andrews concluded.
Clarient combines innovative technologies with world class expertise to
assess and characterize cancer. Clarient's mission is to provide the
services, resources and critical information to improve the quality and
reduce the cost of patient care as well as accelerating the drug
development process. The Company's principal customers include
pathologists, oncologists, hospitals and biopharm
|SOURCE Clarient, Inc.|
Copyright©2007 PR Newswire.
All rights reserved